Establishment of a Screening Protocol for Identification of Aminopeptidase N Inhibitors

Overview

Journal J Taiwan Inst Chem Eng

Publisher Elsevier

Date 2020 Apr 28

PMID 32336998

Citations 9

Authors

Miaomiao Niu

Fengzhen Wang

Fang Li

Yaru Dong

Yueqing Gu

Affiliations

Soon will be listed here.

Abstract

Inhibitors of aminopeptidase N (APN) have been thought as potential drugs for the treatment of tumor angiogenesis, invasion and metastasis and a considerable number of APN inhibitors have been reported recently. To clarify the essential structure-activity relationship for the APN inhibitors as well as identify new potent leads against APN, pharmacophore models were established using structure- and common feature-based approaches and validated with a database of active and inactive compounds. These validated pharmacophores were then used in database screening for novel virtual leads. The hit compounds were further subjected to molecular docking studies to refine the retrieved hits. Finally, six structurally diverse compounds that showed strong interactions with the key amino acids and the zinc ion were selected for biological evaluation, where two hits showed more than 70% inhibition against APN at 60 μM concentration. The evaluation results show the potential of our screening approach in identifying APN inhibitors.

Citing Articles

Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design.

Shen Y, Zhang Y, Wu T, Zhang L, Belviso B Mol Divers. 2024; .

PMID: 39644397 DOI: 10.1007/s11030-024-11072-8.

Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and and biological activity evaluations.

Jin X, Wang Y, Chen J, Niu M, Yang Y, Zhang Q J Enzyme Inhib Med Chem. 2023; 39(1):2289355.

PMID: 38059332 PMC: 11721945. DOI: 10.1080/14756366.2023.2289355.

Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry.

Singh P, Kumar V, Lee G, Jung T, Ha M, Hong J Int J Mol Sci. 2022; 23(24).

PMID: 36555761 PMC: 9784205. DOI: 10.3390/ijms232416122.

Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.

Tian X, Zhao Q, Chen X, Peng Z, Tan X, Wang Q Front Pharmacol. 2022; 13:817715.

PMID: 35264955 PMC: 8899470. DOI: 10.3389/fphar.2022.817715.

Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment.

Lin T, Yang C, Chou C, Hsu J, Chao M, Sung T Biomed Pharmacother. 2021; 146:112459.

PMID: 34953394 PMC: 8776612. DOI: 10.1016/j.biopha.2021.112459.

References

Delmas B, Gelfi J, LHaridon R, Vogel L, Sjostrom H, Noren O . Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature. 1992; 357(6377):417-20. PMC: 7095137. DOI: 10.1038/357417a0. View

Korn J . Aminopeptidase N: a constitutive cell-surface protein on human dermal fibroblasts. Cell Immunol. 1995; 162(1):42-8. DOI: 10.1006/cimm.1995.1049. View

Ma C, Li X, Liang X, Jin K, Cao J, Xu W . Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN). Bioorg Med Chem Lett. 2013; 23(17):4948-52. DOI: 10.1016/j.bmcl.2013.06.058. View

Arooj M, Thangapandian S, John S, Hwang S, Park J, Lee K . 3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors. Int J Mol Sci. 2012; 12(12):9236-64. PMC: 3257128. DOI: 10.3390/ijms12129236. View

Grzywa R, Sokol A, Sienczyk M, Radziszewicz M, Kosciolek B, Carty M . New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010; 18(8):2930-6. DOI: 10.1016/j.bmc.2010.02.056. View

Montiel J, Cornille F, Roques B, Noble F . Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J Neurochem. 1997; 68(1):354-61. DOI: 10.1046/j.1471-4159.1997.68010354.x. View

Li Q, Fang H, Wang X, Hu G, Wang Q, Xu W . Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Bioorg Med Chem Lett. 2011; 22(2):850-3. DOI: 10.1016/j.bmcl.2011.12.048. View

Zhang X, Fang H, Zhu H, Wang X, Zhang L, Li M . Novel aminopeptidase N (APN/CD13) inhibitors derived from 3-phenylalanyl-N'-substituted-2,6-piperidinedione. Bioorg Med Chem. 2010; 18(16):5981-7. DOI: 10.1016/j.bmc.2010.06.078. View

Zini S, Fournie-Zaluski M, Chauvel E, Roques B, Corvol P, Llorens-Cortes C . Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A. 1996; 93(21):11968-73. PMC: 38167. DOI: 10.1073/pnas.93.21.11968. View

10.

Thangapandian S, John S, Sakkiah S, Lee K . Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem. 2010; 45(10):4409-17. DOI: 10.1016/j.ejmech.2010.06.024. View

11.

Lu S, Wu J, Liu H, Zhao J, Liu K, Chuang C . The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci. 2011; 18:8. PMC: 3036604. DOI: 10.1186/1423-0127-18-8. View

12.

John S, Thangapandian S, Arooj M, Hong J, Kim K, Lee K . Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors. BMC Bioinformatics. 2012; 12 Suppl 14:S4. PMC: 3287469. DOI: 10.1186/1471-2105-12-S14-S4. View

13.

Chen H, Roques B, Fournie-Zaluski M . Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999; 9(11):1511-6. PMC: 7172755. View

14.

DIXON J, Kaklamanis L, Turley H, Hickson I, Leek R, Harris A . Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 1994; 47(1):43-7. PMC: 501755. DOI: 10.1136/jcp.47.1.43. View

15.

Purushottamachar P, Patel J, Gediya L, Clement O, Njar V . First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem. 2011; 47(1):412-23. PMC: 3259215. DOI: 10.1016/j.ejmech.2011.11.010. View

16.

Piedfer M, Dauzonne D, Tang R, Nguyen J, Billard C, Bauvois B . Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011; 25(8):2831-42. PMC: 7163944. DOI: 10.1096/fj.11-181396. View

17.

Raynaud F, Bauvois B, Gerbaud P, Evain-Brion D . Characterization of specific proteases associated with the surface of human skin fibroblasts, and their modulation in pathology. J Cell Physiol. 1992; 151(2):378-85. DOI: 10.1002/jcp.1041510219. View

18.

Dearden J . In silico prediction of drug toxicity. J Comput Aided Mol Des. 2003; 17(2-4):119-27. DOI: 10.1023/a:1025361621494. View

19.

Su L, Jia Y, Zhang L, Xu Y, Fang H, Xu W . Design, synthesis and biological evaluation of novel amino acid ureido derivatives as aminopeptidase N/CD13 inhibitors. Bioorg Med Chem. 2012; 20(12):3807-15. DOI: 10.1016/j.bmc.2012.04.035. View

20.

Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T . Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993; 54(1):137-43. PMC: 7165932. DOI: 10.1002/ijc.2910540122. View